OREANDA-NEWS. Sonova Holding AG, the provider of innovative hearing care solutions, today holds its fourth annual Investor & Analyst Day. Senior management will explain the significant value creation potential of the company’s innovation strategy and the power of new products in both hearing instruments and cochlear implants. Sonova will also provide an insight into the development of its next generation 2.4 GHz wireless technology platform, which enables unmatched compatibility and flexibility in terms of future direct communication and connectivity solutions. The event is once again attracting significant interest from the international investor community with over 80 participants expected to attend the day at the headquarters in Stefa, Switzerland.

“We are very pleased to once again share our growth oriented innovation strategy with such a large group of investors and analysts”, says Lukas Braunschweiler, CEO of Sonova. “Our confidence in the future growth potential of our business is underpinned by the continued global expansion of our sales and distribution network and by the success of the Phonak Venture and Unitron North product platforms. We continue to harvest the synergies between Advanced Bionics and Phonak as evidenced by the upcoming introduction of the new Na?da CI sound processors. This, combined with our expanding eSolutions business model, will enable us to keep delivering attractive returns to our shareholders.”

A whole series of new products across all of Sonova’s businesses will be presented today and subsequently be showcased at the EUHA congress starting on 14 October. Among the highlights are:

Phonak

The new custom Phonak Virto V is the latest addition to the Phonak hearing aid portfolio based on the powerful Phonak Venture platform. Running on Phonak’s unmatched new AutoSense OS automation and superior Binaural VoiceStream Technology, Phonak Virto V delivers 15-30% better speech intelligibility1 in noise when compared to two high-end devices of main competitors.The new Floating Antenna enables devices with the full Venture performance to be built with a 25% smaller visible surface area2 than the previous generation. The new design features a faceplate with nano-coated battery doors, new volume controls and a push button which provides 20% better usability3 thanks to its innovative design and placement. Immediately available in four performance levels4, Phonak Virto V offers an even clearer and more natural sound quality as well as up to 30% less battery consumption than the previous generation of custom hearing aids. There is no other hearing aid as small as the Virto V-10 capable of this much performance.

Unitron

Following the introduction of its latest generation of RIC (receiver-in-canal) Moxi hearing instruments based on new product platform North back in April 2015, Unitron is rounding out its offering built on North with Stride, a family of freshly designed BTE (behind-the-ear) and ITE (in-the-ear) hearing instruments. The Stride family of BTE hearing instruments delivers natural sound and enjoyable conversations in all listening environments paired with Unitron’s patient-centric design philosophy aimed at achieving the perfect mix of aesthetics, comfort and intuitive functionality. Customized for comfort, the Stride ITE family offers all the benefits of the North platform in a small package, ranging from the tiny IIC (invisible-in-canal) all the way to full-shell super power instruments. Stride is paired with unique, industry-first solutions such as Flex and Log It All. Log It All enhances Flex by allowing hearing care professionals to gather information from a patient’s experiences wearing hearing instruments to create evidence-based conversations about their lifestyle and technology level choices. The new Unitron Stride products are available later this month in five performance levels.

Advanced Bionics

In the coming months, Advanced Bionics will launch the all-new and comprehensive Na?da CI Q Series. With the powerful new sound processors, Advanced Bionics combines AB’s proven innovations with even more of Phonak’s most popular features relied on by hundreds of thousands of hearing aid users for better hearing in all situations. The Na?da CI Q90 is the top-of-the-line processor and offers new advancements in automation and microphone technology for focusing on speech. New and current Na?da CI Q70 recipients can also benefit from some of the advanced new Q Series features5, including innovations that automatically reduce obtrusive sounds and further improve hearing in difficult environments. Designed to meet the needs of certain select markets, the Na?da CI Q30 offers proven technology that leads the industry for hearing in noise. Also new to the Q Series are PowerCel battery innovations that reduce size and improve battery life.

The slides of the Investor- & Analyst Day presentations are available on the Sonova website on 13 October, 2015 starting at 09.00am CET.

About Sonova

Sonova, headquartered in Staefa, Switzerland, is the leading manufacturer of innovative hearing care solutions. The Group operates through its core business brands Phonak, Unitron, Advanced Bionics and Connect Hearing. Sonova offers its customers one of the most comprehensive product portfolios in the industry – from hearing instruments to cochlear implants to wireless communication solutions. Founded in 1947, the Group is currently present in over 90 countries across the globe and has a workforce of over 10,000 dedicated employees. Sonova generated sales of CHF 2.0 billion in the financial year 2014/15 and a net profit of CHF 368 million. By supporting the Hear the World Foundation, Sonova pursues its vision of a world where everyone enjoys the delight of hearing and therefore lives a life without limitations.

Sonova shares (ticker symbol:SOON, Security no: 1254978, ISIN: CH1012549785) have been listed on the SIX Swiss Exchange since 1994. The securities of Sonova have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or under the applicable securities laws of any state of the United States of America, and may not be offered or sold in the United States of America except pursuant to an exemption from the registration requirements under the U.S. Securities Act and in compliance with applicable state securities laws, or outside the United States of America to non-U.S. Persons in reliance on Regulation S under the U.S. Securities Act.